FY2019 EPS Estimates for Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) Boosted by Jefferies Financial Group

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) – Research analysts at Jefferies Financial Group boosted their FY2019 earnings estimates for Eiger Biopharmaceuticals in a research note issued to investors on Sunday, November 10th. Jefferies Financial Group analyst M. Raycroft now forecasts that the biotechnology company will earn ($0.47) per share for the year, up from their previous forecast of ($0.65). Jefferies Financial Group also issued estimates for Eiger Biopharmaceuticals’ FY2020 earnings at ($2.16) EPS and FY2021 earnings at $0.27 EPS.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($0.76) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by ($0.01).

Several other equities analysts have also issued reports on the stock. ValuEngine lowered shares of Eiger Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th. Zacks Investment Research downgraded shares of Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 8th. LADENBURG THALM/SH SH reaffirmed a “buy” rating and issued a $28.00 target price on shares of Eiger Biopharmaceuticals in a report on Monday. Finally, BidaskClub upgraded shares of Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, October 30th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $28.67.

EIGR stock opened at $11.64 on Wednesday. The company has a market capitalization of $268.17 million, a P/E ratio of -3.05 and a beta of 1.02. The company has a debt-to-equity ratio of 0.44, a quick ratio of 6.83 and a current ratio of 6.83. Eiger Biopharmaceuticals has a 52-week low of $8.40 and a 52-week high of $15.33. The business has a 50-day simple moving average of $10.59 and a two-hundred day simple moving average of $10.76.

Large investors have recently bought and sold shares of the company. BlackRock Inc. lifted its position in shares of Eiger Biopharmaceuticals by 281.9% in the second quarter. BlackRock Inc. now owns 1,729,161 shares of the biotechnology company’s stock worth $18,330,000 after purchasing an additional 1,276,408 shares in the last quarter. Cormorant Asset Management LP acquired a new stake in Eiger Biopharmaceuticals during the second quarter worth $12,190,000. Vanguard Group Inc. boosted its stake in Eiger Biopharmaceuticals by 39.0% during the second quarter. Vanguard Group Inc. now owns 1,070,914 shares of the biotechnology company’s stock worth $11,352,000 after buying an additional 300,279 shares in the last quarter. Farallon Capital Management LLC acquired a new stake in Eiger Biopharmaceuticals during the second quarter worth $10,600,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Eiger Biopharmaceuticals in the 2nd quarter valued at $3,168,000. 82.92% of the stock is owned by institutional investors and hedge funds.

About Eiger Biopharmaceuticals

Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.

Featured Article: What is Put Option Volume?

Earnings History and Estimates for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.